Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome

TY - JOUR

T1 - Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome

AU - Mahler, Michael

AU - Norman, Gary L.

AU - Meroni, Pier Luigi

AU - Khamashta, Munther

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by frequent clotting in arteries and veins and/or miscarriages. Autoantibodies to phospholipids and to beta 2 glycoprotein 1 (β2GP1) play an important role in the pathogenesis of APS. Antibodies to the domain 1 of β2GP1 (β2GP1-D1) have been suggested as a risk marker for thrombosis and to a lesser extent for pregnancy complications in patients suffering from APS. Despite significant interest in anti-β2GP1-D1 antibodies and a considerable research history, the number of studies is still limited and acceptance of the clinical significance of this biomarker is still evolving. The present review summarizes the current knowledge of anti-β2GP1-D1 antibodies and provides insights on recent discoveries. Moreover, we present a suggested guideline for future studies to better understand and verify the clinical utility of anti-β2GP1-D1 antibodies. © 2012 Elsevier B.V.

AB - Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by frequent clotting in arteries and veins and/or miscarriages. Autoantibodies to phospholipids and to beta 2 glycoprotein 1 (β2GP1) play an important role in the pathogenesis of APS. Antibodies to the domain 1 of β2GP1 (β2GP1-D1) have been suggested as a risk marker for thrombosis and to a lesser extent for pregnancy complications in patients suffering from APS. Despite significant interest in anti-β2GP1-D1 antibodies and a considerable research history, the number of studies is still limited and acceptance of the clinical significance of this biomarker is still evolving. The present review summarizes the current knowledge of anti-β2GP1-D1 antibodies and provides insights on recent discoveries. Moreover, we present a suggested guideline for future studies to better understand and verify the clinical utility of anti-β2GP1-D1 antibodies. © 2012 Elsevier B.V.

KW - Antiphospholipid syndrome

KW - APS

KW - Autoantibodies

KW - Beta 2 glycoprotein 1

KW - Domain 1

UR - http://www.scopus.com/inward/record.url?scp=84870255310&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2012.05.006

DO - 10.1016/j.autrev.2012.05.006

M3 - Review article

C2 - 22652408

AN - SCOPUS:84870255310

SN - 1568-9972

VL - 12

SP - 313

EP - 317

JO - AUTOIMMUNITY REVIEWS

JF - AUTOIMMUNITY REVIEWS

IS - 2

ER -